NightHawk revenues soar
Revenue at NightHawk Radiology Holdings jumped 79% in the third quarter, reflecting teleradiology acquisitions as well as a 24% growth in organic operations. Investors were nonplussed, however, by a drop in profit and lowered guidance for revenue and net for the full year 2007. This caused the share price to dip about $0.60 at the market open to $22.98.
Revenue at NightHawk Radiology Holdings jumped 79% in the third quarter, reflecting teleradiology acquisitions as well as a 24% growth in organic operations. Investors were nonplussed, however, by a drop in profit and lowered guidance for revenue and net for the full year 2007. This caused the share price to dip about $0.60 at the market open to $22.98.
Revenue grew to a record $45.2 million compared with $25.2 million in the third quarter 2006. Net income dropped, however, to $3.8 million from $5.6 million in the year earlier period on higher expenses associated with corporate acquisitions, stock compensation, and other liabilities. The company stood by its 2008 guidance of between $215 and $225 million in revenue and $1.31 to $1.36 in adjusted earnings per diluted share.
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
